The protective effects of estrogen on the cardiovascular system

New England Journal of Medicine

Volumn 340, Issue 23, 1999, Pages 1801-1811

  Mendelsohn, Michael E ^a   Karas, Richard H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ION CHANNEL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN;

ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ESTROGEN THERAPY; FIBRINOLYSIS; HUMAN; LIPID BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

BLOOD VESSELS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; RECEPTORS, ESTROGEN;

EID: 0033542402     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199906103402306     Document Type: Review

References (128)

1. Barrett-Connor E. Sex differences in coronary heart disease: why are women so superior? The 1995 Ancel Keys Lecture. Circulation 1997;95: 252-64.
2. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756-62.
3. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016-37.
4. Mendelsohn ME, Karas RH. Estrogen and the blood vessel wall. Curr Opin Cardiol 1994;9:619-26.
5. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9.
6. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J 1996;10:615-24.
7. Walter P, Green S, Greene G, et al. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci U S A 1985;82:7889-93.
8. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JÅ. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925-30.
9. Brzozowski AM, Pike ACW, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-8.
10. Shibata H, Spencer TE, Onate SA, et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res 1997;52:141-65.
11. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-95.
12. Brown M. Estrogen receptor molecular biology. Hematol Oncol Clin North Am 1994;8:101-12.
13. Power RF, Mani SK, Codina J, Conneely OM, O'Malley BW. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 1991;254:1636-9.
14. Karas RH, Gauer EA, Bieber HE, Baur WE, Mendelsohn ME. Growth factor activation of the estrogen receptor in vascular cells occurs via a mitogen-activated protein kinase-independent pathway. J Clin Invest 1998;101:2851-61.
15. Karas RH, Patterson BL, Mendelsohn ME. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994;89: 1943-50.
16. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501-10.
17. Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells: a potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996;94: 727-33.
18. Kim-Schulze S, McGowan KA, Hubchak SC, et al. Expression of an estrogen receptor by human coronary artery and umbilical vein endothelial cells. Circulation 1996;94:1402-7.
19. Caulin-Glaser T, Watson CA, Pardi R, Bender JR. Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 1996;98:36-42.
20. Grohé C, Kahlert S, Löbbert K, et al. Cardiac myocytes and fibroblasts contain functional estrogen receptors. FEBS Lett 1997;416:107-12.
21. Karas RH, Baur WE, van Eickles M, Mendelsohn ME. Human vascular smooth muscle cells express an estrogen receptor isoform. FEBS Lett 1995;377:103-8.
22. Inoue S, Hoshino S, Miyoshi H, et al. Identification of a novel isoform of estrogen receptor, a potential inhibitor of estrogen action, in vascular smooth muscle cells. Biochem Biophys Res Commun 1996;219:766-72.
23. Wingrove CS, Garr E, Godsland IF, Stevenson JC. 17β-Oestradiol enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta 1998;1406:169-74.
24. Ashcroft GS, Dodsworth J, van Boxtel E, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-β1 levels. Nat Med 1997;3:1209-15.
25. Shanker G, Sorci-Thomas M, Adams MR. Estrogen modulates the inducible expression of platelet-derived growth factor mRNA by monocyte/macrophages. Life Sci 1995;56:499-507.
26. Krikun G, Schatz F, Mackman N, Guller S, Lockwood CJ. Transcriptional regulation of the tissue factor gene by progestins in human endometrial stromal cells. J Clin Endocrinol Metab 1998;83:926-30.
27. Citarella F, Misiti S, Felici A, Aiuti A, La Porta C, Fantoni A. The 5′ sequence of human factor XII gene contains transcription regulatory elements typical of liver specific, estrogen-modulated genes. Biochim Biophys Acta 1993;1172:197-9.
28. Davis MD, Butler WB, Brooks SC. Induction of tissue plasminogen activator mRNA and activity by structurally altered estrogens. J Steroid Biochem Mol Biol 1995;52:421-30.
29. Pervin S, Singh R, Rosenfeld ME, Navab M, Chaudhuri G, Nathan L. Estradiol suppresses MCP-1 expression in vivo: implications for atherosclerosis. Arterioscler Thromb Vasc Biol 1998;18:1575-82.
30. Drici MD, Burklow TR, Haridasse V, Glazer RI, Woosley RL. Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation 1996;94:1471-4.
31. Shimizu H, Shimomura Y, Nakanishi Y, et al. Estrogen increases in vivo leptin production in rats and human subjects. J Endocrinol 1997;154: 285-92.
32. Koike H, Karas RH, Baur WE, O'Donnell TF Jr, Mendelsohn ME. Differential-display polymerase chain reaction identifies nucleophosmin as an estrogen-regulated gene in human vascular smooth muscle cells. J Vasc Surg 1996;23:477-82.
33. Kuiper GGJM, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and β. Endocrinology 1997;138:863-70.
34. Paech K, Webb P, Kuiper GGJM, et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997;277:1508-10.
35. Register TC, Adams MR. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor β. J Steroid Biochem Mol Biol 1998;64: 187-91.
36. Iafrati MD, Karas RH, Aronovitz M, et al. Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice. Nat Med 1997; 3:545-8.
37. Lindner V, Kim SK, Karas RH, Kuiper GGJM, Gustafsson J-Å, Mendelsohn ME. Increased expression of estrogen receptor β mRNA in male blood vessels after vascular injury. Circ Res 1998;83:224-9.
38. Cowley SM, Hoare S, Mosselman S, Parker MG. Estrogen receptors α and β form heterodimers on DNA. J Biol Chem 1997;272:19858-62.
39. Yen SSC, Jaffe RB, eds. Reproductive endocrinology: physiology, pathophysiology and clinical management. 3rd ed. Philadelphia: W.B. Saunders, 1991.
40. McDonnell DP. Definition of the molecular mechanism of action of tissue-selective oestrogen-receptor modulators. Biochem Soc Trans 1998; 26:54-60.
41. Bryant HU, Dere WH. Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc Soc Exp Biol Med 1998; 217:45-52.
42. McDonnell DP, Clemm DL, Hermann T, Goldman ME, Pike JW. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995;9:659-69.
43. Knight DC, Eden JA. Phytoestrogens - a short review. Maturitas 1995;22:167-75.
44. Simpson ER, Zhao Y, Agarwal VR, et al. Aromatase expression in health and disease. Recent Prog Horm Res 1997;52:185-213.
45. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 1994;264:1455-8.
46. Mograno MM, Chang W, Katzenellenbogen BS. An estrogen receptor-selective corepressor: cloning and characterization. Endocrinol 1998; 98:96.
47. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208. [Erratum, JAMA 1995;274:1676.]
48. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
49. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997;96:1964-9.
50. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:721-6.
51. Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 1993;328:1069-75.
52. The Writing Group for the Estradiol Clotting Factors Study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a one-year, double-blind, placebo-controlled study. Thromb Haemost 1996;75:476-80.
53. Salomaa V, Rasi V, Pekkanen J, et al. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors: the FINRISK Hemostasis Study. Arterioscler Thromb Vasc Biol 1995;15: 1549-55.
54. Koh KK, Mincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336:683-90.
55. Gebara OCE, Mittleman MA, Sutherland P, et al. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study. Circulation 1995;91:1952-8.
56. Schunkert H, Danser AHJ, Hense HW, Derkx FHM, Kurzinger S, Riegger GAJ. Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 1997;95:39-45.
57. Proudler AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, Stevenson JC. Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Lancet 1995;346:89-90.
58. Ylikorkala O, Orpana A, Puolakka J, Pyorala T, Viinikka L. Postmenopausal hormonal replacement decreases plasma levels of endothelin-1. J Clin Endocrinol Metab 1995;80:3384-7.
59. 1 receptor gene expression in vitro and in vivo. Circulation 1998;97:2197-201.
60. Best PJM, Berger PB, Miller VM, Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med 1998;128:285-8.
61. Sugioka K, Shimosegawa Y, Nakano M. Estrogens as natural antioxidants of membrane phospholipid peroxidation. FEBS Lett 1987;210:37-9.
62. Liehr JG. Antioxidant and prooxidant properties of estrogens. J Lab Clin Med 1996;128:344-5.
63. Shwaery GT, Vita JA, Keaney JF Jr. Antioxidant protection of LDL by physiological concentrations of 17β-estradiol: requirement for estradiol modification. Circulation 1997;95:1378-85.
64. Wiseman H. The antioxidant action of a pure antioestrogen: ability to inhibit lipid peroxidation compared to tamoxifen and 17β-oestradiol and relevance to its anticancer potential. Biochem Pharmacol 1994;47:493-8.
65. Santanam N, Shern-Brewer R, McClatchey R, et al. Estradiol as an antioxidant: incompatible with its physiological concentrations and function. J Lipid Res 1998;39:2111-8.
66. Sack MN, Rader DJ, Cannon RO III. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994;343:269-70.
67. Arnal JF, Clamens S, Pechet C, et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. Proc Natl Acad Sci U S A 1996;93:4108-13.
68. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
69. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature 1994;372:231-6. [Erratum, Nature 1994;372:812.]
70. Jiang C, Sarrel PM, Lindsay DC, Poole-Wilson PA, Collins P. Endothelium-independent relaxation of rabbit coronary artery by 17β-oestradiol in vitro. Br J Pharmacol 1991;104:1033-7.
71. Kitazawa T, Hamada E, Kitazawa K, Gaznabi AKM. Non-genomic mechanism of 17β-oestradiol-induced inhibition of contraction in mammalian vascular smooth muscle. J Physiol (Lond) 1997;499:497-511.
72. 2+ uptake. Circ Res 1997;81: 242-8.
73. Cs channels through a cGMP-dependent mechanism. Circ Res 1995;77:936-42.
74. + channels. Circ Res 1996;79:1024-30.
75. Chen Z, Yuhanna IS, Galcheva-Gargova ZI, Karas RH, Mendelsohn ME, Shaul PW. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103:401-6.
76. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, Shaul PW. Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol 1997;273:L119-L126.
77. 2+ mobilization. Circ Res 1997;81:885-92.
78. Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 1997;59:365-93.
79. Pappas TC, Gametchu B, Watson CS. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J 1995;9:404-10.
80. ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996;15:1292-300.
81. Garcia-Cardena G, Fan R, Shah V, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 1998;392:821-4.
82. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol 1992;20:452-7.
83. Sudhir K, Ko E, Zellner C, et al. Physiological concentrations of estradiol attenuate endothelin 1-induced coronary vasoconstriction in vivo. Circulation 1997;96:3626-32.
84. Reis SE, Gloth ST, Blumenthal RS, et al. Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women. Circulation 1994;89:52-60.
85. Gilligan DM, Quyyumi AA, Cannon RO III. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994;89:2545-51.
86. Gilligan DM, Badar DM, Panza JA, Quyyumi AA, Cannon RO III. Acute vascular effects of estrogen in postmenopausal women. Circulation 1994;90:786-91.
87. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-41.
88. Collins P, Rosano GMC, Sarrel PM, et al. 17β-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
89. Guetta V, Quyyumi AA, Prasad A, Panza JA, Waclawiw M, Cannon RO III. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997;96:2795-801.
90. Blumenthal RS, Heldman AW, Brinker JA, et al. Acute effects of conjugated estrogens on coronary blood flow response to acetylcholine in men. Am J Cardiol 1997;80:1021-4.
91. Reis SE, Bhoopalam V, Zell KA, et al. Conjugated estrogens acutely abolish abnormal cold-induced coronary vasoconstriction in male cardiac allografts. Circulation 1998;97:23-5.
92. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet 1993;342:133-6.
93. Weiner CP, Lizasoain I, Baylis SA, Knowles RG, Charles IG, Moncada S. Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A 1994;91:5212-6.
94. Binko J, Majewski H. 17β-Estradiol reduces vasoconstriction in endothelium-denuded rat aortas through inducible NOS. Am J Physiol 1998; 274:H853-H859.
95. Collins P, Shay J, Jiang C, Moss J. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation 1994;90:1964-8.
96. Keaney JF Jr, Shwaery GT, Xu A, et al. 17β-Estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 1994;89:2251-9.
97. Rubanyi GM, Freay AD, Kauser K, et al. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta: gender difference and effect of estrogen receptor gene disruption. J Clin Invest 1997;99:2429-37.
98. Williams JK, Adams MR, Klopfenstein HS. Estrogen modulates responses of atherosclerotic coronary arteries. Circulation 1990;81:1680-7.
99. Williams JK, Honoré EK, Adams MR. Contrasting effects of conjugated estrogens and tamoxifen on dilator responses of atherosclerotic epicardial coronary arteries in nonhuman primates. Circulation 1997;96: 1970-5.
100. McCrohon JA, Walters WAW, Robinson JTC, et al. Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol 1997;29:1432-6.
101. New G, Timmins KL, Duffy SJ, et al. Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol 1997;29:1437-44.
102. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73: 951-2.
103. Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998; 97:1234-8.
104. Roqué M, Heras M, Roig E, et al. Short-term effects of transdermal estrogen replacement therapy on coronary vascular reactivity in postmenopausal women with angina pectoris and normal results on coronary angiograms. J Am Coll Cardiol 1998;31:139-43.
105. Sudhir K, Chou TM, Messina LM, et al. Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet 1997; 349:1146-7.
106. Sudhir K, Chou TM, Chatterjee K, et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 1997;96:3774-7.
107. Morales DE, McGowan KA, Grant DS, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995;91:755-63.
108. Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM, Losordo DW. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997;95:1768-72.
109. Spyridopoulos I, Sullivan AB, Kearney M, Isner JM, Losordo DW. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis: estradiol as a survival factor. Circulation 1997;95:1505-14.
110. Cornwell TL, Arnold E, Boerth NJ, Lincoln TM. Inhibition of smooth muscle cell growth by nitrk oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol 1994;267:C1405-C1413.
111. Kolodgic FD, Jacob A, Wilson PS, et al. Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol 1996;148: 969-76.
112. Bhalla RC, Toth KF, Bhatty RA, Thompson LP, Sharma RV. Estrogen reduces proliferation and agonist-induced calcium increase in coronary artery smooth muscle cells. Am J Physiol 1997;272:H1996-H2003.
113. Cid MC, Kleinman HK, Grant DS, Schnaper HW, Fauci AS, Hoffman GS. Estradiol enhances leukocyte binding to tumor necrosis factor (TNF)-stimulated endothelial cells via an increase in TNF-induced adhesion molecules E-selectin, intercellular adhesion molecule type 1, and vascular cell adhesion molecule type 1. J Clin Invest 1994;93:17-25.
114. Sullivan TR Jr, Karas RH, Aronovitz M, et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 1995;96: 2482-8.
115. Bourassa PAK, Milos PM, Caynor BJ, Breslow JL, Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1996;93:10022-7.
116. Levine RL, Chen SJ, Durand J, Chen YF, Oparil S. Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation 1996;94:2221-7.
117. Oparil S, Levine RL, Chen SJ, Durand J, Chen YF. Sexually dimorphic response of the balloon-injured rat carotid artery to hormone treatment. Circulation 1997;95:1301-7.
118. Clarkson TB, Anthony MS, Klein KP. Effects of estrogen on arterial wall structure and function. Drugs 1994;47:Suppl 2:42-51.
119. Nathan L, Chaudhuri G. Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol 1997;37:477-515.
120. Hanke H, Hanke S, Bruck B, et al. Inhibition of the protective effect of estrogen by progesterone in experimental atherosclerosis. Atherosclerosis 1996;121:129-38.
121. Lou H, Kodama T, Zhao YJ, et al. Inhibition of transplant coronary arteriosclerosis in rabbits by chronic estradiol treatment is associated with abolition of MHC class II antigen expression. Circulation 1996;94:3355-61.
122. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75.
123. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61. [Erratum, N Engl J Med 1996;335:1406.]
124. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997;79:847-50.
125. O'Brien JE, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996;28:1111-8.
126. O'Keefe JH Jr, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997;29:1-5.
127. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
128. Braunwald E. Shattuck Lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 1997;337:1360-9.